1. Volume 119, Issue 1, Pages 41-50 (July 2000)
Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans 
Bernard Coulie, Lawrence A. Szarka, Michael Camilleri, Duane D. Burton, Sanna McKinzie, Nancy Stambler, Jesse M. Cedarbaum 
Gastroenterology 
Volume 119, Issue 1, Pages (July 2000)
DOI: /gast
Copyright © 2000 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Experimental protocol of 6-week studies with 2-week lead-in, 2-week treatment, and 2-week washout periods.
Gastroenterology  , 41-50DOI: ( /gast )
Copyright © 2000 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Scintigraphic scans showing the effects of r-metHuBDNF and placebo on colonic transit in individual participants. Treatment with r-metHuBDNF resulted in acceleration of colonic transit, with more isotope located in the more distal segment of the colon, and a corresponding increase in GC with r-metHuBDNF treatment.
Gastroenterology  , 41-50DOI: ( /gast )
Copyright © 2000 American Gastroenterological Association Terms and Conditions

4. Fig. 3
Individual data for GC at (A) 24 and (B) 48 hours before and after treatment. Data for r-metHuBDNF are shown on the left, and data for placebo on the right. The mean data for each group are indicated by the thick horizontal bar. Most participants who received r-metHuBDNF had higher GC24 values after treatment.
Gastroenterology  , 41-50DOI: ( /gast )
Copyright © 2000 American Gastroenterological Association Terms and Conditions

5. Fig. 4
Number of stools per week in the (A) placebo-treated group and (B) r-metHuBDNF–treated group. Placebo or drug was administered in weeks 1 and 2. Individual data points, median and interquartile ranges, and 10th and 90th percentiles (horizontal lines) are shown. The r-metHuBDNF group had an increased stool frequency from the first week of treatment; this effect persisted for a week after cessation of NT administration.
Gastroenterology  , 41-50DOI: ( /gast )
Copyright © 2000 American Gastroenterological Association Terms and Conditions

6. Fig. 5
Scintigraphic scans showing the effects of r-metHuNT-3 on colonic transit in a constipated participant. Treatment with r-metHuNT-3 resulted in acceleration of colonic transit, with more isotope located in the more distal segment of the colon, and a corresponding increase in GC with r-metHuNT-3 treatment.
Gastroenterology  , 41-50DOI: ( /gast )
Copyright © 2000 American Gastroenterological Association Terms and Conditions

7. Fig. 6
Results of scintigraphic scans showing the effects of r-metHuNT-3 on gastric, small bowel, and colonic transit in constipated participants. Individual data points, median and interquartile ranks, and ranges (horizontal lines) are shown. Treatment with r-metHuNT-3 resulted in acceleration in gastric, small bowel, and colonic transit. SBTT, small bowel transit time; GEt½, gastric half-emptying time.
Gastroenterology  , 41-50DOI: ( /gast )
Copyright © 2000 American Gastroenterological Association Terms and Conditions

8. Fig. 7
Individual data for GC at (A) 24 and (B) 48 hours before and after treatment with r-metHuNT-3 in patients with constipation. Mean data for each group are indicated by thick horizontal bars. Dashed lines represent the lower limit of normal based on values obtained in 57 healthy subjects in our laboratory (unpublished data).
Gastroenterology  , 41-50DOI: ( /gast )
Copyright © 2000 American Gastroenterological Association Terms and Conditions

9. Fig. 8
Number of stools per week in (A) constipation and (B) health. r-metHuNT-3 was administered in weeks 1 and 2. The figure shows individual data points, median and interquartile ranges, and ranges (horizontal lines). Both groups showed increased frequency from the first week of treatment; this effect persisted for a week after cessation of NT administration.
Gastroenterology  , 41-50DOI: ( /gast )
Copyright © 2000 American Gastroenterological Association Terms and Conditions

10. Fig. 9
(A) In constipated patients, ease of stool passage was altered during r-metHuNT-3 treatment compared with baseline. (B) Stool consistency tended to be softer during treatment (2, baseline; ■, on treatment).
Gastroenterology  , 41-50DOI: ( /gast )
Copyright © 2000 American Gastroenterological Association Terms and Conditions